This was the stock's second consecutive day of gains.
Selected preclinical small molecule candidates will now be tested through the Quris-AI platform prior to initiating clinical trials. This follows a successful two-year validation study with Merck KGaA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback